Becoming ‘biologic-like’: CAR-T makers on quest to scale drugs’ production

Last year was a tough one for CAR T-cell therapies.

A FDA review in November culminated in a class-wide boxed warning requirement on the risk of secondary blood cancers. It spanned all approved drugs in the class of autologous CAR-Ts, sans Tecartus and followed the agency’s unofficial acknowledgement of a probable causal link.

Still, the category is poised for an upswing.